New semaglutide pill put to the test in healthy volunteers
NCT ID NCT05784402
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested a new tablet version of the drug semaglutide in 264 healthy volunteers. The goal was to measure how much of the drug gets into the blood with the new tablet compared to the current version. Participants took different doses over 21 weeks to see which formulation provides the best drug levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide
What this could lead to
If successful, this study could help develop a more effective or convenient oral version of semaglutide, potentially improving treatment options for conditions like diabetes or obesity.
What could go wrong
This is an early Phase 1 study in healthy volunteers, not patients. It only measures drug levels in the blood, not actual treatment effects. The new formulation may not prove better or safer in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences Clinical Company, Inc
Montreal, Quebec, H3P 3P1, Canada
-
Altasciences Clinical Kansas, Inc.
Kansas City, Kansas, 66212, United States
-
Altasciences Clinical LA, Inc.
Cypress, California, 90630, United States